Search
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedIt has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. … Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae).
Categories: Heterocyclic Compounds with 4 or More RingsRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalIn contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Hydroflumethiazide
go.drugbank.com/drugs/DB00774ApprovedWithdrawnA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Categories: combinations of sulfonamidesDaraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalThe ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years. … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Ethoxzolamide
go.drugbank.com/drugs/DB00311ApprovedWithdrawnEthoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.
Categories: combinations of sulfonamidesArazasetron
go.drugbank.com/drugs/DB19237InvestigationalArazasetron is currently under investigation in clinical trial NCT05258773 (Evaluation of the Presence of SENS-401 in the Perilymph).
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawnXanthinol is a very potent water-soluble derivative of niacin that can be found in diet supplements. It is also known as xanthinol nicotinate. … [L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Synonyms: N-Hydroxyurea, N-Carbamoylhydroxylamine